Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.

ABSTRACT:

Background

The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known.

Hypothesis

This 10-week, double-blind trial examined the relative safety and efficacy of valsartan administered qd versus twice-daily (bid).

Methods

HF patients (NYHA class II-III) receiving diuretics (87%), angiotensin-converting enzyme inhibitors (98%), beta-blockers (92%), aldosterone antagonists (25%), or digoxin (32%) were randomized to valsartan 40 mg bid (n = 60) or 80 mg qd (n = 55) and titrated to a maximum dose of 320 mg/day; doubling the dose every 2 weeks. Clinical and biochemical parameters were measured at Weeks 2, 4, 6, and 10.

Results

The average dose of valsartan at the end of study was 245 mg in the bid group vs 256 mg in the qd group (P =

SUBMITTER: Anand IS 

PROVIDER: S-EPMC2922305 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature